Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 24;9(1):11-21.
doi: 10.1159/000536107. eCollection 2024 Jan-Dec.

Crosstalk between MicroRNAs and Oxidative Stress in Coeliac Disease

Filippo Pelizzaro  1   2 , Romilda Cardin  1 , Giulia Sarasini  1 , Milena Minotto  1 , Chiara Carlotto  1 , Matteo Fassan  3   4 , Michela Palo  1 , Fabio Farinati  1   2 , Fabiana Zingone  1   2
Affiliations
Review

Crosstalk between MicroRNAs and Oxidative Stress in Coeliac Disease

Filippo Pelizzaro et al. Inflamm Intest Dis. .

Abstract

MicroRNAs (miRNAs) are small, non-coding RNA molecules involved in regulating gene expression. Many studies, mostly conducted on pediatric patients, suggested that oxidative stress and several miRNAs may play an important role in coeliac disease (CeD) pathogenesis. However, the interplay between oxidative stress and miRNA regulatory functions in CeD remains to be clarified. In this review, we aimed to perform a literature review on the role of miRNAs and oxidative stress in adult CeD patients and to analyze their potential interactions. In this direction, we also reported the preliminary results of a pilot study we recently performed.

Keywords: Coeliac disease; Diagnosis; Inflammation; MicroRNAs; Oxidative stress.

PubMed Disclaimer

Conflict of interest statement

Matteo Fassan has a consulting or advisory role for Astellas Pharma, GlaxoSmithKline, Roche, MSD Oncology, Amgen, Lilly, Incyte, Novartis, AstraZeneca, and Pierre Fabre, and research funding for Astellas Pharma, QED Therapeutics, Macrophage Pharma, and Diaceutics. Fabiana Zingone has served as a speaker for Werfen, EG Stada Group, Fresenius Kabi, Kedrion, Janssen, Pfizer, Takeda, Unifarco, Malesci, and Galapagos and has served as a consultant for Galapagos and Takeda. Filippo Pelizzaro served as a consultant for EISAI and MSD. Romilda Cardin, Giulia Sarasini, Milena Minotto, Chiara Carlotto, Michela Palo, and Fabio Farinati have no conflicts of interest to declare.

Figures

Fig. 1.
Fig. 1.
The crosstalk of miRNAs and oxidative stress. a ROS regulates the expression and biogenesis of miRNAs through the control of proteins involved in post-transcriptional events, through the upregulation of transcription factors and through epigenetic alterations. b miRNAs modulate ROS production through regulating several redox signaling pathways, thus regulating intracellular redox homeostasis.
Fig. 2.
Fig. 2.
miRNAs levels in CeD patients at diagnosis (CeD-dia), CeD patients after at least 1 year of GFD (CeD-GFD), and control patients (CP) (a–h).
See this image and copyright information in PMC

References

    1. Ludvigsson JF, Bai JC, Biagi F, Card TR, Ciacci C, Ciclitira PJ, et al. . Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. Gut. 2014;63(8):1210–28. - PMC - PubMed
    1. Lenti MV, Aronico N, Bianchi PI, D’Agate CC, Neri M, Volta U, et al. . Diagnostic delay in adult coeliac disease: an Italian multicentre study. Dig Liver Dis. 2023;55(6):743–50. - PubMed
    1. Singh P, Arora A, Strand TA, Leffler DA, Catassi C, Green PH, et al. . Global prevalence of celiac disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(6):823–36.e2. - PubMed
    1. Pelizzaro F, Marsilio I, Fassan M, Piazza F, Barberio B, D’Odorico A, et al. . The risk of malignancies in celiac disease: a literature review. Cancers. 2021;13(21):5288. - PMC - PubMed
    1. Giuffrida P, Di Sabatino A. MicroRNAs in celiac disease diagnosis: a miR curiosity or game-changer? Dig Dis Sci. 2020;65(7):1877–9. - PubMed